SCHEMBL6470547

SCHEMBL6470547

CN(C)c1nc(N)nc(N)c1C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 2/20 0.37
HRH2 P25021 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GALR3 O60755 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HRH4 Q9H3N8 4/20 0.33
PSMB5 P28074 2/20 0.33
CCNA2 P20248 3/20 0.31
CDK2 P24941 3/20 0.31
CCNA1 P78396 2/20 0.31
NUDT1 P36639 1/20 0.31
PIK3CA P42336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469727 0.85 PSMB5 (0.38) ADKHRH2HRH3MEN1KMT2A
SCHEMBL6470544 0.77 HRH2 (0.49) ADKHRH2HRH3HRH4PSMB5
SCHEMBL6473619 0.77 HRH2 (0.40) HRH2HRH3MEN1KMT2AGALR3
SCHEMBL6469725 0.75 HRH2 (0.46) ADKHRH2HRH3HRH4PSMB5
SCHEMBL5539983 0.71 PSMB5 (0.36) ADKHRH3ALDH1A1CYP1A2HRH4
SCHEMBL604272 0.70 DNM2 (0.38) HRH2HRH3MEN1KMT2AHRH4
SCHEMBL6471048 0.68 HRH2 (0.32) HRH2HRH3
SCHEMBL4409611 0.68 PSMB5 (0.31) PSMB5
SCHEMBL24566192 0.67 KDM4E (0.41) HRH2HRH3ALDH1A1CYP1A2HRH4
SCHEMBL606789 0.67 HRH4 (0.51) HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 ADK 1450/4885HRH2 43/4885HRH3 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.